Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.
Solriamfetol is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy with or without cataplexy. This publication reviews its efficacy and safety, and the limitations of the evidence.
Solriamfetol is also licensed to improve wakefulness and reduce EDS in adults with obstructive sleep apnoea (see separate RDTC evaluation).